These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25053390)

  • 21. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.
    Remon J; Morán T; Reguart N; Majem M; Carcereny E; Lianes P
    Cancer Treat Rev; 2014 Jul; 40(6):723-9. PubMed ID: 24759598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
    Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
    J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
    Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
    Ovcaricek T; Cufer T; Kern I; Sodja E; Sadikov A
    J Cancer Res Ther; 2013; 9(2):261-6. PubMed ID: 23771370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Palacio S; Pontes L; Prado E; Arshad J; Ali R; Piha T; Bacchi CE; Mudad R; Lopes G
    Oncologist; 2019 Apr; 24(4):e137-e141. PubMed ID: 30446583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutation testing for squamous cell lung carcinoma.
    Liam CK; Leow HR; Pang YK
    J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
    [No Abstract]   [Full Text] [Related]  

  • 35. Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.
    Zakowski MF; Rekhtman N; Auger M; Booth CN; Crothers B; Ghofrani M; Khalbuss W; Laucirica R; Moriarty AT; Tabatabai ZL; Barkan GA
    Arch Pathol Lab Med; 2016 Oct; 140(10):1116-20. PubMed ID: 27552093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Cobas® EGFR Mutation Test v2 assay.
    Brown P
    Future Oncol; 2016 Feb; 12(4):451-2. PubMed ID: 26838018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
    Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
    Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR analysis: current evidence and future directions.
    Bellevicine C; Malapelle U; de Luca C; Iaccarino A; Troncone G
    Diagn Cytopathol; 2014 Nov; 42(11):984-92. PubMed ID: 24619906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.
    Peters M; Kim ES; Hirsch V
    J Glob Oncol; 2019 Feb; 5():1-7. PubMed ID: 30811306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncologists push beyond new lung cancer genomic testing guidelines.
    Garber K
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25677038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.